Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - March 2013


18th Congress of The European Association of Hospital Pharmacists (EAHP)

13 Mar 2013 - 15 Mar 2013 - Palais des Congrès, Paris, France



Bookmark and Share


The European Association of Hospital Pharmacists (EAHP) is a working community of national associations of hospital pharmacists. Membership is increasing each year and, at present, EAHP represents the interest of over 21,000 hospital pharmacists in 32 countries all over Europe.

EAHP’s annual congress is the largest congress for hospital pharmacy in Europe and is attended by professionals from over 50 countries. Approximately 4.000 hospital pharmacists are expected to attend the 18th Congress of the EAHP next 13-15 March 2013 at the Palais des Congrès in Paris, France.

“Improving patient outcomes – a shared responsibility”  will be the theme for the presentations at the Paris 2013 EAHP Congress. A scientific programme including 3 keynote presentations, 13 seminars open for interactions with the speakers and 3 interactive workshops will offer participants the unique opportunity to meet, network and share expertise. EAHP’s industry partners have also committed to conducting satellite symposia highlighting important new developments important to hospital pharmacy.

EAHP’s Congress is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education, as well as by some of its national member associations according to the different national accreditation systems.

REGISTRATION OPEN 1 AUGUST 2012:
Register online to attend the EAHP 18th Congress.

CALL FOR ABSTRACTS: 
Deadline for submission is 15 October 2012.  Original contributions from all fields of hospital pharmacy are welcomed for poster presentation. 

For further information, please visit the website, where you will also be able to find more details on our scientific programme.

The registration fees are set follows :

 

— before 1 December 2012  € 600

— beginning 1 December 2012 € 700

— beginning 1 February 2013 € 800

 

Registration fee includes access to all sessions, the opening reception, the exhibition, lunches on Wednesday, Thursday, Friday and coffee/tea during official breaks.

 

Registration fee includes 19,6% VAT until 1 October and 21,2% afterwards according to French law.



Further information
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!